Remove Contract Manufacturing Remove Development Remove Gene
article thumbnail

Ajinomoto spices up its biopharma business with gene therapy deal

Bio Pharma Dive

Forge Biologics operates a contract manufacturing business as well as develops its own gene therapies, which appears to have attracted the Japan-based food and biotechnology company.

article thumbnail

Forge Biologics and Labcorp partner for gene therapies development

Pharmaceutical Technology

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years. The same is true for the biopharmaceutical contract services market.

article thumbnail

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

Roots Analysis

Over the last few decades, the development landscape of small molecule drugs has been significantly impacted by various biotechnology breakthroughs. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years. The same is true for the biopharmaceutical contract services market.

article thumbnail

CDMO Bionova branches into plasmid DNA to serve cell and gene therapy developers

Fierce Pharma

As Japanese chemical giant Asahi Kasei continues its foray into the biopharma contract manufacturing space, the company’s biologics CDMO is expanding its offerings to include starting materials for | Asahi’s U.S.

DNA 104
article thumbnail

Bespoke Gene Therapy Consortium Selects 8 Rare Diseases for Clinical Trial Portfolio

XTalks

The Foundation for the National Institutes of Health (FNIH) announced this week that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio.

article thumbnail

Exothera - a company starting from R&D in small volumes then scaling out using robotics

BioPharma Reporter

Patrick Thiaville is chief scientific officer of Exothera Nucleic Acids, a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies.